The estimated Net Worth of Philippe Amouyal is at least $1.64 Million dollars as of 28 April 2024. Mr. Amouyal owns over 8,032 units of Lexicon Pharmaceuticals Inc stock worth over $419,735 and over the last 17 years he sold LXRX stock worth over $1,133,850. In addition, he makes $90,959 as Independent Director at Lexicon Pharmaceuticals Inc.
Sign up
Mr. Amouyal LXRX stock SEC Form 4 insiders trading
Philippe has made over 8 trades of the Lexicon Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 8,032 units of LXRX stock worth $13,574 on 28 April 2024.
The largest trade he's ever made was buying 200,000 units of Lexicon Pharmaceuticals Inc stock on 13 November 2023 worth over $202,000. On average, Philippe trades about 5,445 units every 45 days since 2007. As of 28 April 2024 he still owns at least 248,364 units of Lexicon Pharmaceuticals Inc stock.
You can see the complete history of Mr. Amouyal stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Philippe Amouyal biography
Philippe J. Amouyal serves as Independent Director of the Company. Previously, Mr. Amouyal has been a director since August 2007 and is a managing director of The Invus Group, LLC, a position he has held since 1999. Previously, Mr. Amouyal was a vice president and director of The Boston Consulting Group, Inc. in Boston, Massachusetts, where he coordinated the global technology and electronics practice through most of the 1990s. Mr. Amouyal is a director of WW, Inc., as well as a number of private companies in which Invus has invested. He previously served as a director of Blue Buffalo Pet Products, Inc. from 2007 until April 2018 when Blue Buffalo was acquired by General Mills, Inc. Mr. Amouyal holds an M.S. in engineering and a DEA in management from Ecole Centrale de Paris and was a research fellow at the Center for Policy Alternatives of the Massachusetts Institute of Technology.
What is the salary of Philippe Amouyal?
As the Independent Director of Lexicon Pharmaceuticals Inc, the total compensation of Philippe Amouyal at Lexicon Pharmaceuticals Inc is $90,959. There are 14 executives at Lexicon Pharmaceuticals Inc getting paid more, with Lonnel Coats having the highest compensation of $3,870,290.
How old is Philippe Amouyal?
Philippe Amouyal is 61, he's been the Independent Director of Lexicon Pharmaceuticals Inc since 2007. There are 9 older and 9 younger executives at Lexicon Pharmaceuticals Inc. The oldest executive at Lexicon Pharmaceuticals Inc is Alan Nies, 82, who is the Independent Director.
What's Philippe Amouyal's mailing address?
Philippe's mailing address filed with the SEC is 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS, TX, 77381.
Insiders trading at Lexicon Pharmaceuticals Inc
Over the last 18 years, insiders at Lexicon Pharmaceuticals Inc have traded over $161,951 worth of Lexicon Pharmaceuticals Inc stock and bought 392,158,422 units worth $731,672,961 . The most active insiders traders include International S.C.A.Minne P..., International S.C.A.Wittouc... und Llc Invus, L.P.Invus Adviso.... On average, Lexicon Pharmaceuticals Inc executives and independent directors trade stock every 43 days with the average trade being worth of $5,348,701. The most recent stock trade was executed by International S.C.A.Wittouc... on 10 May 2024, trading 57,546,100 units of LXRX stock currently worth $97,252,909.
What does Lexicon Pharmaceuticals Inc do?
corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio
What does Lexicon Pharmaceuticals Inc's logo look like?
Complete history of Mr. Amouyal stock trades at Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals Inc executives and stock owners
Lexicon Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Lonnel Coats,
President, Chief Executive Officer, Director -
Praveen Tyle,
Executive Vice President - Research and Development -
Jeffrey Wade,
Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs -
Lonnel Coats,
CEO & Director -
Alan Main,
Executive Vice President, Commercial Supply Operations -
Jeffrey L. Wade J.D.,
Pres & CFO -
Dr. Alan J. Main Ph.D.,
Exec. VP of Innovation & Chemical Sciences -
Dr. Alan J. Main,
Exec. VP of Innovation & Chemical Sciences -
Brian T. Crum,
VP, Gen. Counsel & Sec. -
James Tessmer,
Vice President - Finance and Accounting -
Raymond Debbane,
Independent Chairman of the Board -
Samuel Barker,
Independent Director -
Frank Palantoni,
Independent Director -
Judith Swain,
Independent Director -
Philippe Amouyal,
Independent Director -
Robert Lefkowitz,
Independent Director -
Christopher Sobecki,
Independent Director -
Alan Nies,
Independent Director -
Dr. Robert J. Lefkowitz,
Consultant & Independent Director -
Brian Crum,
Vice President, General Counsel -
Dr. Craig B. Granowitz M.D., Ph.D.,
Sr. VP & Chief Medical Officer -
Kristen L. Alexander,
VP of Fin. & Accounting -
Chas Schultz,
Exec. Director of Corp. Communications & Patient Advocacy -
Sam L Barker,
Director -
Alexander A Santini,
EVP and CCO -
Pablo Lapuerta,
EVP and CMO -
International S.C.A.Wittouc...,
-
Us Partners Llc Ulys, L.L.C...,
-
Tamar D Howson,
EVP of Bus Dev -
Barry Mills,
Director -
Julia P Gregory,
EVP and CFO -
James R Phd Piggott,
SVP of Pharm Bio -
Lance K Ishimoto,
SVP, Intellectual Property -
Clayton Stuart Rose,
Director -
Public Equities, L.P.Artal ...,
-
Public Equities, L.P.Artal ...,
-
International S.C.A.Minne P...,
-
Diane E. Sullivan,
Director -
Thomas Garner,
SVP, Chief Commercial Officer -
Arthur T Sands,
Pres & CEO -
John Northcott,
VP, Marketing, Comm Strategy -
Cv Ulys, L.L.C.Debbane Raym...,
-
International S.C.A.Minne P...,
-
Brian P Zambrowicz,
EVP, Chief Scientific Officer -
Llc Invus, L.P.Invus Public...,
-
International S.C.A.Invus, ...,
-
Kathleen M Wiltsey,
Director -
Llc Invus, L.P.Invus Adviso...,
-
Philip M Brown,
SVP Clinical Development -
Steven Alan Tragash,
VP, Corporate Affairs -
Llc Invus, L.P.Invus Adviso...,
-
Ajay Bansal,
EVP Corp Dev and CFO -
Kristen Alexander,
VP, Finance and Accounting -
C.V. Invus,
Director -
Craig B Granowitz,
SVP, Chief Medical Officer -
Kenneth B. Kassler Taub,
SVP, Regulatory & QA -
Wendy Mc Dermott,
VP, Human Resources -
Kiernan Seth,
VP, Chief Commercial Officer -
Michael Exton,
Chief Executive Officer -
Brian Corrigan,
SVP, Regulatory & QA